Telix and Varian Announce Strategic Theranostics - EBRT Clinical...

Telix and Varian Announce Strategic Theranostics - EBRT Clinical Collaboration
https://telixpharma.com/news-views/telix-and-varian-announce-strategic-theranostics-ebrt-clinical-collaboration/

• What is this?
• What does it mean?
• Whats the relevance to Cu6?

External Beam Radiation Therapy (EBRT) is the most commonly used radiation method for treating cancer. It works and it’s been reliable for decades.
But, but it carries a problem as old as radiotherapy itself:EBRT doesn’t only hit what you are going after (the cancer) - it hits everything in its path.That means skin, muscle, healthy tissue, and even nearby organs can absorb radiation simply because they sit between the machine and the tumour.


EBRT is effective, but by its very nature it causes collateral damage.

Focussing on prostate prostate cancer: Radiation oncologists have historically taken the simple (but imperfect) approach - Just irradiate the whole prostate (if still present) and prostate bed, or the area where the prostate was if post prostatectomy, plus surrounding region.Yes, you fry some healthy tissue, but its worked “well enough” because the alternatives were not as good! And it is still being done!

But what about the escaped cancer? You need to find it accurately before you can direct EBRT to the right spots. CT and MRI have been the standard staging tools, but they miss disease!

Enter PSMA PET and Telix’s strategy: The idea is to move the industry into using PSMA PET in radiation planning! PSMA PET is good at detecting not just the disease inside the prostate, but it detects metastatic spread as well, and does so earlier than bone scan, CT and MRI. It provides a map for targeted radiation. You can then zap the lesions more accurately, and also follow them to some other treatable areas where they may have escaped to. This technology makes it possible to target smalllesions while they are still small! GENIUS!

Remember COBRA and Co-PSMA?

If EBRT planning moves toward high-precision, high-accuracy lesion detection (as it absolutely must), then the choice of tracer becomes inevitable, not debatable: The tracer that sees more, sees earlier, and sees smaller will dominate. Full stop.

You don’t need a PSMA PET scan to find golf-ball-sized lesions - a plain X-ray can do that.The entire value of PET lies in early, accurate, and even microscopic disease detection if you can get there! And now, with EBRT workflows moving toward molecularly-guided targeting, everything is aligning:

• More precision
• More individualised treatment
• More reliance on accurate lesion mapping
• More clinical situations where diagnostic sensitivity isn’t optional - it’s foundational

It is all coming together so beautifully.There has never been a better time to be Clarity Pharmaceuticals.

Thank you, Telix, for what is a Clarity positive announcement!